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Moringa oleifera Lam. (Moringaceae) is one of the many medicinal plants employed by herbalist to treat 
or manage people living with HIV/AIDS (PLWHA) in African Traditional Medicine (ATM) and there are 
many claims to the fact that it improves quality of life and reverses the course of the HIV/AIDS disease 
progression. This practice and the claims of efficacy spurred the present study in which the inhibitory 
activities of three different extracts of M. oleifera on lentiviral vector infectivity were studied on HeLA 
cells by measuring the expression of green fluorescent protein (GFP) transgene in the vector using flow 
cytometry. An infectious VSV-G-pseudotyped, human immunodeficiency virus type 1-based, self-
inactivating lentiviral vector particles were generated by transient co-transfection of the vector plasmid 
(pHIV-1 CSCG) with packaging plasmids encoding tat, rev, gag-pol (pCMVΔR8.2), a VSV-G expression 
plasmid (pHIT-G), a secretory alkaline phosphate expression plasmid (pSEAP) which are all necessary 
for viral infectivity. The extracts studied were obtained by solvent extraction of the leaf powder of M. 
oleifera with ethyl ether (EM), methanol (MM) and water (AM). All the extracts (EM, MM, and AM) were 
active against the HIV-1 lentiviral vector and inhibited the early events of the viral replication cycle on 
HeLa cells in a concentration-dependent manner with IC50 of 7.59 µg EM/ml, 7.72 µg MM/ml and 7.17 µg 
AM/ml, respectively. Cytotoxicity of the extracts evaluated in parallel on HeLA cells by the MTT assay 
method showed TC50 values of 32.33 µg EM/ml, 38.88 µg MM/ml and 41.58 µg AM/ml with  selectivity 
indices (SI) of 4.26, 5.04 and 5.8, respectively. In this study, M. oleifera leaf extracts showed potent and 
selective inhibition of early steps in HIV-1 infectivity and could serve as source of antiretroviral lead 
molecules. The outcome of this investigation could partly explain the benefits and improvement in 
quality of life claimed by PLWHA in the use of this medicinal plant as supplement.   
 






Medicinal plants have been widely used to treat a variety 
of infectious  and  non-infectious ailments. The  existence  
of the humankind has been under constant threat by 
emerging infectious disease; prominent among these are
 





infections associated with the human immunodeficiency 
virus. HIV/AIDS does not have a curative therapy yet and 
currently available options are management therapies. 
Although, a lot of progress has been made in the recent 
times, the accessibility and affordability of anti-retroviral 
medications in middle and low-income countries with high 
prevalence rate of HIV/AIDS infections are still knotty 
issues (UNAIDS, 2012) and heavily depend on the 
benevolence of international donor agencies. Although, 
the adoption of highly active antiretroviral therapy 
(HAART) regimen has been largely successful in 
reducing viral load, increasing quality of life (QoL) and life 
expectancy and in decreasing HIV-related complications; 
this has however come at a high price (Harrington and 
Carpenter, 2000). HIV rapidly evolves resistance to these 
antiretroviral agents, unless taken precisely on schedule; 
even short lapses in taking the pills can lead to resistance 
(Richman, 2004; Cane, 2009). Additionally, these drugs 
cause a variety of minor and serious adverse effects.  
Due to the unsatisfactory efficacy, high cost, non-
availability and intolerable adverse effects of conventional 
antiretroviral medicines, People Living with HIV/AIDS 
(PLWHA) often seek alternative and complementary 
therapies including herbal medicines. It has been 
reported that due to the chronic course and the effect of 
the HIV-related diseases on quality of life and the 
possibility of severe complications and death, people with 
HIV/AIDS are very likely to seek herbal therapies (Ernst, 
1997; Ozsoy and Ernst, 1999; Faragon et al., 2002), 
particularly in poor countries and in rural communities 
with limited access to the highly active anti-retroviral 
therapy (HAART). Even in developed countries like the 
United States, some surveys have found that HIV-
infected people use herbal remedies and made 
substantially high expenses on complementary and 
alternative therapies (CAM) and have also reported much 
improvement with these treatments (Fairfield et al., 1998; 
Wootton and Sparber, 2001). The increased patronage of 
CAM could have been informed by the growing body of 
knowledge and the accumulation of anecdotal scientific 
evidences which establishes their safety and 
effectiveness in reducing HIV load, strengthening 
immune system functions, and tackling the many and 
diverse immunodeficiency-related opportunistic 
infections. 
The efficacy and the benefits claimed by CAM 
providers as well as patients who use these herbal 
remedies are too remarkable to ignore. Investigation into 
these herbal remedies could hold the key to some potent 
and safe alternative therapies or could uncover lead 
molecules for further development. Investigation into local 
herbal remedies for anti-retroviral activities has been the 
focus of some of our recent investigations (Esimone et 
al., 2009, 2010; Okoye et al., 2012). In the present study, 
the activity of different extracts of Moringa oleifera Lam 
(Monringaceae) against HIV-1 lentiviral vector infectivity 
in a viral vector-based assay was undertaken. M. oleifera  




(commonly called drumstick tree or horseradish tree) is a 
very versatile plant with many valuable medicinal and 
nutritional uses and found widely in tropical and 
subtropical regions of the world. Many bioactive 
phytoconstituents have been reported in different parts of 
the plant, such as beta-carotene, proteins, vitamins and 
variety of phenolics (Siddhuraju and Becker, 2003; Anwar 
et al., 2007). M. oleifera is rich in zeatin, quercetin, beta-
sitosterol, caffeoylquinic acid and kaempferol, a rare 
combination of important bioactive compounds 
(Siddhuraju and Becker, 2003; Anwar et al., 2007). 
Various parts of this plant such as the leaves, roots, 
seed, bark, fruit, flowers and immature pods have been 
reported to act as cardiac and circulatory stimulants 
(Duke, 2001; Nandave et al., 2009), have antitumor  
(Guevaraa et al., 1999; Parvathy and Umamaheshwari, 
2007), antipyretic (Hukkeri et al., 2006), anti-inflammatory 
(Muangnoi et al., 2012), antiulcer (Rujjanawate et al., 
2004; Debnath and Guha, 2007), antispasmodic (Gilani 
et al., 1994), diuretic (Morton, 1991), antihypertensive 
(Gilani et al., 1994), cholesterol lowering (Ghasi et al., 
2000), antioxidant (Singh et al., 2009), antidiabetic 
(Ndong et al., 2007), hepatoprotective (Pari and Kumar, 
2002) and antibacterial and antifungal activities (Chuang 
et al., 2007; Saadabi and Abu Zaid, 2011) and for these 
reasons have been employed in folk and Ayurvedic 
traditional medicine of Africa and South Asia for a variety 
of medicinal purposes. In African Traditional Medicine 
(ATM), M. oleifera is one of the many medicinal plants 
employed by herbalist to treat or manage PLWHA and 
there are so many claims on its effectiveness in 
improving quality of life and in reversing the course of the 
HIV/AIDS disease progression. For this reason, our 
present study has been devoted to studying different 
solvent extracts of M. oleifera for antiretroviral activity 
using a viral vector-based assay technique. 
Research on anti-viral medicinal plants has been 
limited by the shortcomings of the available screening 
techniques. Traditional methods of evaluating antiviral 
agents have involved one or more of the following in vitro 
techniques: plaque inhibition assay, plaque reduction 
assay, inhibition of virus-induced cytopathic effect, virus 
yield reduction assay, end point titre determination assay, 
reduction or inhibition of the synthesis of virus-specific 
polypeptides, immunological assays detecting viral 
antigens and viral enzyme inhibition-based assays 
(Vlietinck and Vanden Berghe, 1991; Cowan, 1999). 
While these methods have successfully been employed 
to screen many and diverse antiviral agents, limitations 
and shortcomings relating to safety, long assay period, 
cumbersomeness, experimental-biased read-out, high 
cost and the inability to distinguish between mere toxic 
effects of agents on host cells and selective antiviral 
effects associated with some of these methods has 
limited their application in high throughput assays of the 
vast and yet to be screened medicinal plants with 
potential  antiviral  activities (Esimone et  al., 2005,  2007; 
  




Okoye et al., 2012).  
In this study, we have used a modification of a rapid 
and reproducible vector-based antiviral screening 
technique as earlier described (Esimone et al., 2005, 
2010) to screen three different solvent extracts of the 
plant M. oleifera (Moringaceae) for anti-retroviral activity. 
This technique is novel and a high throughput approach 
for the screening of medicinal plant extracts for possible 
antiviral activities (Esimone et al., 2005).  
 
 
MATERIALS AND METHODS 
 
Collection and extraction of plant materials 
 
Fresh leaves of M. oleifera plants were collected from Nibo in 
Awka-south L.G.A, Anambra State, Nigeria. The identity was 
authenticated by Prof. C. C. Okeke of the Department of Botany, 
Nnamdi Azikiwe University, Awka. The plant leaves were washed, 
dried and ground to powder using a mechanical grinder. The 
methanol extract (MM) and petroleum ether extracts (EM) were 
obtained by macerating 40 g portions of the plant powder in 200 ml 
of either methanol or petroleum ether for 48 h at room temperature 
with intermittent agitation. The solutions were filtered using 
Whatman No 1 filter paper and concentrated to dryness in vacuo at 
40°C. The aqueous extract (AM) was also obtained by macerating a 
40 g portion of the plant powder in 400 ml of distilled water at room 
temperature for 24 h. The resulting solution was concentrated by 




Phytochemical analysis of plant extracts  
 
The extracts (EM, MM and AM)  was tested for the presence of 
alkaloids, flavonoids, tannins, saponins, glycosides, protein, 
carbohydrate, terpenoids, resins, fats and oil, steroids and reducing 






Human embryonic kidney cells expressing SV40 Large T-antigen 
(293 T) and Henrietta Lacks cells were propagated in D-10 medium, 
consisting of Dulbecco’s modified Eagle’s medium (DMEM) with 
high glucose, 2 mM L-glutamine and supplemented with 10% heat-
inactivated foetal bovine serum (FBS), 100 U/ml penicillin and 100 
µg/ml streptomycin. Tissue culture medium and supplements were 
purchased from Invitrogen (Karlsruhe, Germany). The cell cultures 
were maintained in a humidified 5% CO2 atmosphere at 37°C. 
 
 
Generation of HIV-1 viral vectors transferring GFP genes 
 
Infectious HIV lentiviral particles transferring the Green Fluorescent 
Protein (GFP) gene were generated by transient co-transfection of  
GFP-expressing vector constructs based on HIV-1 (pHIV-CSCG, 5 
µg), Vesicular stomatitis virus- G (VSV-G) protein expression 
plasmid (pHIT-G, 2 µg), a secretory alkaline phosphate expression 
plasmid (pSEAP, 0.1 µg)  and the HIV-1 codon-optimised gag-pol, 
tat, rev expression plasmids pCMVΔR8.2 using polyethyleneimine 
(PEI) transfection protocol (Wagner et al., 2000) in 293T cells. The 
cells were sub-cultured and transfected during the log growth phase 









Vector-based antiviral assay 
 
The effect of the test extracts on HIV-1 vector infectivity was 
determined according to a previously described technique (Wagner 
et al., 2000; Esimone et al., 2005). HeLa cells were plated in 
triplicates into 96-well plates at a density of 6000 cells/well and 
incubated overnight. Various concentrations of the test extracts (at 
twice the final concentrations indicated) were prepared in DMEM 
(without FBS) such that the final DMSO concentration does not 
exceed 0.5%. These various concentrations were pre-incubated 
with equal volumes of the HIV-1 vector supernatant (100 µl) for 30 
min at 37°C. Culture medium from the HeLa cell monolayers was 
replaced with 50 µl of the above vector/drug mixtures in triplicates 
and incubated for 2 h at 37°C + 5% CO2. Fresh D-10 medium (50 µl) 
containing the drugs at the final concentrations stated were then 
added and the culture was incubated for two days. Control wells 
(containing vector alone but without drug) received D-10 medium 
containing 0.5% DMSO instead. The number of infected cells 
expressing the green fluorescent protein (GFP) was determined by 
FACS acquisition (FACScalibur
TM
 flow cytometer, Becton 




Cytotoxicity assay  
 
The cytotoxicity assay was performed in parallel to the antiviral 
screening using the MTT assay method as previously described 
(Esimone et al., 2005) on HeLa cells. In the MTT assay, cells were 
seeded onto a 96-well plate at a concentration of 10
4
 cells/well and 
a volume of 100 µl per well. A volume of 100 µl of the different 
concentrations of the test extracts (5, 25 and 62.5 µg/ml) were 
added to culture wells in triplicate. Culture medium without any drug 
was used as the “no-drug” control. After incubation at 37°C under 
5% CO2 for 2 days, a solution of MTT (3 mg/ml, 50 µl per well) was 
added to each well and further incubated at 37°C + 5% CO2 for 4 h 
to allow formazan formation. After this time, the medium was 
removed and 150 µl of DMSO was used to dissolve the resulting 
blue formazan crystals in living cells. The optical density was 
determined at 550 nm using a multi-well microtitre plate reader 
(Tecan, Austria). Each single value of the triplicates was expressed 
as percentage of the mean of triplicates of the “no-drug” control 
cultures and the mean and standard deviation of the percent values 
were calculated for each triplicate. The concentration of 50% 
cellular toxicity (TC50) of the test extracts was calculated by non-





Phytochemical analysis  
 
The phytochemical analysis of the different solvent 
extracts of M. oleifera showed the presence of saponins, 
alkaloids, glycosides, tannins, carbohydrates, flavonoids, 
resins, acidic compounds and proteins. Ether extract of 
M. oleifera contained only alkaloids and flavonoids while 
the aqueous extract contained saponins, alkaloids, 
glycosides, tannins, carbohydrates, acidic compound, 





Table 1. Relative abundance of different 




EM AM MM 
Saponins _ +++ ++ 
Alkaloids ++++ +++ ++ 
Glycosides - +++ +++ 
Tannins - ++++ +++ 
Carbohydrates - ++ + 
Reducing sugar - - - 
Flavonoids ++++ - ++ 
Resins + - ++ 
Steroids - - - 
Terponoids - - - 
Fats and oil - - - 
Acidic compounds - +++ - 
Proteins - + ++ 
 
 -, Not present; +, present in small concentration; 
++, present in moderately high concentration; +++, 
































































Figure 1. Inhibitory effect of aqueous extract of M. oleifera 




relatively higher phytochemicals constituents as 
compared to other solvent extracts (Table 1). 
 
 
Viral vector infectivity inhibitory studies and 
cytotoxicity 
 
Flow cytometry and FACS analysis of viral infectivity rate 
showed that the aqueous extract of M. oleifera  (AM) was 
active against the HIV-1 lentiviral vector and inhibited the 
early events of the viral replication cycle on HeLa cells in 
a concentration-dependent manner (5 to 62.5 µg/ml) 
(Figure 1). Inhibition of viral vector infectivity of HeLa 
cells was about 77.51% as compared to the untreated 
control cells at 62.5 µg AM/ml. A concentration of 7.17 µg 
AM/ml  inhibited 50%  of  the viral vector infectivity  (IC50).  




Table 2. Antiviral selectivity indices of M. oleifera extracts against 
HIV-1 lentiviral vector. 
 
Parameter  AM MM EM 
TC50 (µg/ml) 41.58 38.88 32.33 
IC50 (µg/ml) 7.17 7.72 7.59 
Selectivity index (TC50/IC50) 5.80 5.04 4.26 
 
AM, Aqueous extract of M. oleifera; EM, ether extract of M. oleifera; 
MM, methanolic extract of M. oleifera; IC50, concentration of extract that 
inhibited viral infectivity (cytopathic effect) by 50%; TC50, concentration 


































































Figure 2. Inhibitory effect of methanol extract of M.oleifera 




The 50% cytotoxic concentration (TC50) was 41.58 µg 
AM/ml in the assay performed by MTT assay in parallel 
with the study on viral vector infectivity inhibition. This 
implies an inhibition selectivity index (SI) of 5.80 for the 
aqueous extract of M. oleifera (Table 2). 
The methanol extract of M. oleifera  (MM) showed 
inhibition of 50% of viral infectivity (IC50) at a 
concentration of 7.72 µg MM/ml while cytotoxicity of 50% 
of the cells (TC50) was at 38.88 µg MM/ml thus giving a 
selectivity index of  5.0 (Table 2). Inhibition of viral vector 
infectivity of HeLa cells was about 75.33% as compared 
to the untreated control cells at 62.5 µg MM/ml and the 
cells were still up to 70% viable at this concentration  
(Figure 2).  
The ether extract of M. oleifera (EM) inhibited 50% of 
viral infectivity (IC50) of HeLA cells at a concentration of 
7.59 µg EG/ml while 32.33 µg EM/ml was cytotoxic to 
50% of the cells. This implies a viral inhibition selectivity 
index of 4.26 (Table 2). The percentage inhibitions of viral 
infectivity of EM (5, 25 and 62.5 µg/ml) were 28.2, 75.6 
and 76.6%, respectively. The cells were still viable by 





Despite unrelenting research efforts and huge spending, 
HIV/AIDS is  still a daunting challenge and burden to  glo- 
  

















































Figure 3. Inhibitory effect of ether extract of M. oleifera 




bal public health and there are still no cure or effective 
vaccines against the disease. Presently, the use of 
prevention strategies and highly active antiretroviral 
therapy (HAART) are the best options available to 
decrease morbidity and mortality due to HIV/AIDS. 
Several classes of antiretroviral drugs have been 
developed and used mostly in combinations to target viral 
proteins at different stages of the HIV life cycle or host 
factors. The HAART cocktail uses a nucleoside reverse 
transcriptase inhibitor (NRTI) and/or a nonnucleoside 
reverse transcriptase inhibitor in combination with either a 
protease inhibitor (PI), fusion inhibitor (FI), CCR5 
antagonist or an integrase inhibitor (II) to treat PLWHA 
(Henkel, 1999; Bartlett, 2004; USDHHS, 2012). Some of 
the major limitations of current antiretroviral drugs are the 
constant emergence of multi-resistant strains of HIV, 
intolerable adverse side effects, and the 
unavailability/affordability of these drugs in poor 
countries; especially in sub-Saharan Africa where 
HIV/AIDS is rampaging. Therefore, developing cost-
effective, safe, highly specific drugs that will be less 
susceptible to development of resistance by HIV is an 
urgent unmet need.  
It has long been recognised that natural products, 
especially those derived from plants, are excellent 
sources of new anti-HIV-1 drugs (De Clercq, 2000, 2005; 
Esimone et al., 2009, 2010, 2012). Some of these plants-
derived antiretroviral therapies have been shown to have 
inhibitory activities against several HIV-1 processes, 
including viral entry, reverse transcription, replication, 
integration, virus maturation and virion budding. Some of 
these compounds have been clinically tested, with 
favourable results (Asres et al., 2005; Park et al., 2009; 
Vo and Kim, 2010; Jiang et al., 2010; Filho et al., 2010; 
Sing and Bodiwala, 2010).  
In the present study, we used a novel vector-based 
assay technique to screen lipophilic and polar solvent 
extracts of the plant, M. oleifera for inhibitory activities 





VSV-G-pseudotyped, human immunodeficiency virus 
type 1-based, self-inactivating lentivirus vector expres-
sing green fluorescent protein (GFP) under the control of 
Cytomegalovirus (CMV) promoter was constructed and 
used as viral infective particles on HeLa cells. The 
infectious vector particles were generated by transient 
co-transfection of the vector plasmid (pHIV-1 CSCG) with 
packaging plasmids encoding tat, rev, gag-pol 
(pCMVΔR8.2), a VSV-G expression plasmid (pHIT-G), a 
secretory alkaline phosphate expression plasmid 
(pSEAP) all necessary for viral infectivity. Transient 
supply of the packaging plasmids and the self-inactivation 
of the vector by deletion of the U3 region in the 3
1
-LTR to 
make sure that the resulting lentiviral vector is only 
capable of a single round of replication, makes the viral 
vectors comparatively safer than their parent wild 
retroviral virus. The infectious vector particles additionally 
differ from the wild-type HIV-1 virus in that they lacked 
some of the HIV-1 accessory genes such as nef, vif, vpu 
and vpr. Because the transgene (in this case, Green 
fluorescent protein) is integrated into the genome of 
target cells in the process of infection, vector infectivity in 
the presence or absence of various concentrations of the 
extracts is easily determined by flow cytometrically as a 
function of the amount of GFP expression. In this system, 
GFP expression is driven by an internal CMV promoter 
and occurs after integration. The implication is that 
inhibitors of late stages in viral replication cycle such as 
inhibitors of new viral assemblage and inhibitors of 
budding are not detected by the screening assay used in 
the study. However, this cell-based assay is one of the 
high-throughput screening techniques used to identify 
new inhibitors that target different steps in the HIV-1 life 
cycle. Single-cycle infectious pseudotyping of HIV-1 
using the envelope glycoprotein of the vesicular 
stomatitis virus (VSV-G) can mimic some activities of the 
wild-type viruses (Aiken, 1997). 
For the pilot screening of potential anti-HIV medicinal 
plants, this vector based assay used in this study offers 
multiple advantages. Firstly, it reduces the risk of working 
with the wild type HIV-1 while retaining the sensitivity and 
reliability of the assay. Fear of the risks associated with 
working with wild type HIV-1 viruses has deterred many 
investigators from evaluating potential anti-HIV medicinal 
plant extracts, especially in less developed countries with 
limited resources and ill-equipped laboratories. Secondly, 
pseudo-typing of the vector with the VSV-G envelope 
ensures a wider cell tropism. Therefore, antiviral 
screening is not only confined to cell lines which express 
CD4 and/or CCR5 receptors (Esimone et al., 2007). The 
viral vector can infect a range of other cell lines. Thirdly, 
the assay is very rapid. Read out is obtained in about two 
days as opposed to 5 to 10 days for many conventional 
anti-HIV screening techniques. Fourthly, read out is 
simple and highly reproducible as opposed to the 
cumbersome procedure of enumerating HIV-induced 






tion of viral infectivity is simple and devoid of experiment-
tal bias and therefore reproducible. Fifthly, it is possible to 
make a clear distinction between direct antiviral effect of 
plant extract and the mere cytotoxic effects of the extract 
to target cell lines.  
Results of the study show that the different solvent 
extracts of M. oleifera inhibit early events in the viral 
replication cycle. The selectivity index of the M. oleifera 
extracts (4.26to 5.80) against the HIV-1 lentiviral vector is 
sufficiently high and demonstrates that the antiviral 
activities observed are not due to the cytotoxicity of the 
extracts on HeLa cells used in the study.  Previously, the 
structure of a bioactive thiocarbamate, niaziminin, 
extracted from the leaf of M. oleifera was shown to be 
enough in inhibiting the activation of a tumour promoting 
virus, EpsteinBarr virus (EBV) (Murakami et al., 1998). It 
has also been reported in earlier studies that M. oleifera 
leaf may be applicable as a prophylactic or therapeutic 
anti-HSV (Herpes simplex virus type 1) medicine and 
may be effective against the acyclovir-resistant variant of 
the virus (Lipipun et al., 2003). In another recent study, 
hydroalcoholic extract of M. oleifera fruits showed anti-
hepatitis B virus (HBV) activity (Waiyaput et al., 2012).  
In this investigation, preliminary phytochemical analysis 
of the extracts of M. oleifera showed, generally, the 
presence of saponins, alkaloids, glycosides, tannins, 
carbohydrates, flavonoids, resins, acidic compounds and 
proteins. Previously, M. oleifera has been shown to be 
rich in compounds containing the simple sugar, 
rhamnose and a fairly unique group of compounds called 
glucosinolates and isothiocyanates (Fahey et al., 2001; 
Bennett et al., 2003). Two alkaloids moringine and morin-
ginine (Kerharo, 1969), vanillin, β-sitosterol, β-sitoste-
none, 4-hydroxymellin and octacosanoic acid have been 
isolated from the stem of M. oleifera (Faizi et al., 1994). 
Although, the specific contribution of these phytochemical 
constituents is yet to be investigated, the antiretrovial 
activities of M. oleifera could be attributed to some of 
these phytoconstituents in the extracts. Tannins which 
were found present in M. oleifera have been shown in 
earlier studies to prevent a variety of viral infections 
(Serafini et al., 1994; Nonaka et al., 1990). Tannins have 
also been demonstrated to inhibit viral reverse transcript-
tase (Nonaka et al., 1990). Similarly, flavonoids have 
been shown to show inhibitory effects against viruses 
including HIV and respiratory syncytial virus (Li et al., 
2000). Plant-derived flavonoids have been reported to 
inhibit critical steps in the life cycle of HIV infectivity such 
as viral entry (Liu et al., 2011), reverse transcriptase (Li 
et al., 2011), integrase (Lee et al., 2003; Tewtrakul et al., 
2003), viral transcriptional activities of HIV tat (Mehla et 
al., 2011) and protease inhibitory activities (Lee et al., 
2009) and other activities. M. oleifera is also rich in 
saponins which have been reported to inhibit HIV 
infectivity, in vitro (Konoshima et al., 1995; Yang et al., 
1999; Li et al., 2012). 
In this study, the extracts  of M. oleifera potently  inhibi- 




ted HIV-1 lentiviral vector infectivity and cytotoxicity 
studies conducted in parallel show that the inhibition of  
viral vector infectivity of these extracts are not due to 
diminished viability of the cells induced by the extracts. 
The extracts selectively inhibited viral infectivity of the 
cells. In earlier studies, correlations between anti-HIV-1 
vector activity and anti-wild type HIV-1 activity have been 
demonstrated. In one of such studies, Steinstraesser et 
al. (2005) demonstrated in an assay that the porcine 
defensin (protegrin-I) showed more than three-fold high-
er activity against the wild type HIV-1 than against the 
corresponding lentiviral vector. It was also shown that 
some antiviral medicinal plant extracts showed up to ten-
fold higher activities against wild type lentiviruses as 
against the corresponding lentiviral vector particles 
(Esimone et al., 2005). This is very instructive and points 
to the reliability of the high through-put viral vector 
particles-based assay in the screening of putative 
substances for antiviral activities. It also suggests that the 
extracts screened in this study using the lentiviral HIV-I 
vector could show higher antiviral activities when used 
against wild type HIV-I virus. The pattern of inhibition of 
the HIV lentiviral vector suggests that the extracts either 
directly interacted with the vector particles inhibiting the 
envelope protein or that it interacted with some host cells-
derived components of the viral particle which could be 
the lipid membrane derived from the cell or the cellular 
membrane proteins that are often incorporated in 
lentiviral particles during budding (Gould et al., 2003).    
Interestingly, some studies and reports suggest that 
extracts from M. oleifera could be deployed for its 
nutritive and immune-boosting properties to support 
PLWHA. The proceedings of the 14th International AIDS 
Conference held in Barcelona, Spain in 2002 included a 
recommendation that M. oleifera powder be considered 
as an alternative treatment to boost the immune systems 
of HIV-positive patients in Africa who would otherwise not 
receive antiretroviral drugs or, in fact, any treatments at 
all (Burger et al., 2002). Similarly, the widespread conco-
mitant use of M. oleifera with antiretroviral drugs by 
PLWHA in East Africa, the benefits, as well as the 
potential for herb/drug interactions has also been docu-
mented (Monera and Maponga, 2012). The outcome of 
this study, which showed that early steps in the infectivity 
of HIV-1 lentiviral vector particles are inhibited by leaf 
extracts of M. oleifera, could lend credence to its wide-
spread use among PLWHA. The study suggests that, 
apart from its nutritive values and strengthening of the 
immune system which are widely reported, retroviral 
inhibitory activities of M. oleifera leaf extracts could partly 
explain the benefits and improvement in quality of life 
claimed by PLWHA in the use of this medicinal plant as 





In this study, M. oleifera Lam. leaf extracts showed potent 
  




and selective inhibition of HIV-1 infectivity and could 
serve as source of antiretroviral lead molecule. The 
outcome of this investigation could partly explain the 
benefits claimed in the use of extracts of M. oleifera in the 
management/treatment of People Living with HIV/AIDS in 
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